FDA orders boxed warning for Takeda’s ADZYNMA after fatal antibody case, mandating postmarketing studies and enhanced monitoring.
The U.S. Food and Drug Administration (FDA) has ordered major safety labeling changes for ADZYNMA after postmarketing reports of neutralizing antibodies to ADAMTS13, including one fatal case in patients with congenital thrombotic thrombocytopenic purpura (cTTP). ADZYNMA, the first recombinant ADAMTS13 replacement therapy, received FDA approval in November 2023.
The FDA first disclosed the safety concern on November 21, 2025, when it announced an investigation into a fatal case involving neutralizing antibodies to ADAMTS13 after ADZYNMA treatment in a cTTP patient.
Boxed Warning and Monitoring Requirements
Under Section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act, the FDA directed Takeda Pharmaceuticals U.S.A., Inc. to add a boxed warning highlighting the risk of neutralizing antibodies to ADAMTS13. The agency also required strengthened immunogenicity warnings and close monitoring of ADAMTS13 activity and antibody development in all treated patients.
Clinicians are advised to assess patients for inhibitors if expected ADAMTS13 activity levels are not achieved or if acute exacerbations occur despite appropriate dosing.
The FDA also noted that currently available assays cannot distinguish whether inhibitory antibodies target recombinant, endogenous, or plasma-derived ADAMTS13, which may complicate interpretation of laboratory results.
Clinical Trial Data
Neutralizing antibodies were not observed during ADZYNMA clinical trials. All trial participants had prior exposure to plasma-based ADAMTS13 products, and no immunogenicity data are currently available in previously untreated patients.
The updated patient package insert will warn that inhibitors may be life-threatening and could prevent ADZYNMA from working properly. Patients are also advised to undergo regular blood-test monitoring for inhibitor development.
Postmarketing Studies Ordered
To further evaluate immunogenicity risk, the FDA has mandated two postmarketing studies:
- A prospective multicenter interventional trial evaluating immunogenicity and clinical loss of efficacy in severe cTTP patients receiving prophylactic or on-demand treatment.
- A non-interventional real-world safety study following commercially treated patients for at least 12 months.
Formal Safety Labeling Change Order
On May 20, 2026, the FDA escalated the matter by issuing a formal Safety Labeling Change Order after determining that Takeda’s proposed revisions did not adequately address the newly identified safety risk.
Under the order, Takeda must submit a Changes Being Effected (CBE) supplement implementing all FDA-requested modifications by June 4, 2026. Required updates include additions to the boxed warning, revisions to Section 5.2 on immunogenicity, and updates to Section 12.6.
The FDA also warned that failure to comply could result in civil monetary penalties and could render the product misbranded under federal law.
Regulatory Significance
The FDA’s decision to require a boxed warning for ADZYNMA highlights increasing regulatory scrutiny of postmarketing immunogenicity risks associated with biologic replacement therapies. The action also underscores the agency’s willingness to mandate labeling revisions when serious safety concerns emerge after approval.
Reference
Notification Safety Labeling Change Postmarketing Requirement – ADZYNMA
